This study aimed to elucidate the role of PAK1 in pancreatic cancer, by examining the effects of reduction of PAK1 expression by shRNA knock-down, or PAK1 activity with the selective inhibitor FRAX597, on the growth and migration/invasion of pancreatic cancer cell lines in vitro, and in orthotopic murine models in vivo, alone and in combination with gemcitabine. This evidence concerns the gene PAK1 and pancreatic neoplasm.